

## LETTERS

### **Prescribing generic drugs using a generic name: Are we teaching it right?**

The Indian Medical Council (Professional conduct, Etiquette and Ethics) Regulations, 2002, state that "Every physician should, as far as possible, prescribe drugs with generic names and he/she shall ensure that there is a rational prescription and use of drugs."<sup>(1)</sup> Undergraduate medical students are introduced to drug nomenclature early on during their pharmacology course. They are told that generic name or, more appropriately, non-proprietary name (usually international non-proprietary name INN), is to be used while writing prescriptions. However, not enough emphasis is placed on explaining the nuances of the terms "generic drugs" (unbranded), "branded (innovator) drugs" and "branded generics", probably because they are not important in that time context. Subsequently these issues are usually never dealt with in an academic context. Generic drugs are produced by pharmaceutical companies once an innovator drug is off-patent. Innovator drugs and branded generics have unique brand names of their own while the latter is more economical to varying degrees since no clinical trials need to be conducted to establish its efficacy and safety. The Indian drug market is essentially composed of branded generics with huge price differences between some of them while branded (innovator) drugs and unbranded generics account for only a small percentage (2). Pharmacies and drug stores other than in government-run hospitals and clinics hardly stock unbranded generic drugs. When a prescription is received for an unbranded generic drug it is likely that the pharmacist would dispense his/her favourite branded generic instead. Even when unbranded generics are available there are concerns among the prescribers regarding the efficacy and safety of low cost generics. In such a scenario, asking doctors to prescribe using generic name only serves to avoid dispensing errors due to look-alike, sound-alike brand names and illegible prescriptions (nonetheless important). The emphasis placed on writing prescriptions using generic names in undergraduate education when neither the hospitals nor the pharmacies/drug stores indent (unbranded) generic drugs seems somewhat misplaced and probably demoralising.

In the United States, the emphasis is on prescribing generic drugs over branded (innovator) drugs because of the huge cost difference between the two. The percentage of branded generics in the market is not as high as in India. Moreover, the Orange book published by the United States Food and Drug Administration provides assurance to health professionals as well as the public regarding the quality of the approved generics (branded and unbranded) (3). It is imperative that the Indian health agencies ensure availability of unbranded generics in all places, at all times, and in adequate amounts. Also important is to ensure that suitable measures are taken

to satisfy the general concern regarding the quality of such products. Unless this is ensured, we would not be completely justified in asking our students to write generic names in the prescription when we know that no such (unbranded) generics actually exist to be dispensed, nor is the pharmacist bound to give out the cheapest brand of a drug by law.

**Ashwin Kamath** ([ashwin.kamath@manipal.edu](mailto:ashwin.kamath@manipal.edu)), Associate Professor, Department of Pharmacology, Kasturba Medical College, Manipal University, Mangalore, Karnataka, 575 001, INDIA

#### **References**

1. Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 [cited 2015 Nov 27]. Available from: <http://www.mciindia.org/Rules-and-Regulation/Ethics%20Regulations-2002.pdf>.
2. Srinivas I. The myth of branded generics. *Econ Pol Wkly*. 2014 Sep 20 [cited 2015 Nov 27]; 49(38). Available from: <http://www.epw.in/commentary/myth-branded-generics.html>.
3. US Department of Health and Human Services. Approved drug products with therapeutic equivalence evaluations. 35<sup>th</sup> ed. USA; 2015 [cited 2015 Nov 27]. Available from: <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf>.

### **Conversion therapy for homosexuality: serious violation of ethics**

Across the world, homosexuality is gaining legitimacy; stigma and discrimination are gradually giving way to equality and inclusion. The situation in India is in stark contrast to these trends. In this country, homosexuality is an offence as per Section 377 of the IPC. The homosexual community is fighting for its rights and continues to suffer from intense stigma and discrimination. Their healthcare needs are not at all attended to; their sexual orientation is conceptualised as a socially deviant mental disease that needs psychiatric treatment (1).

Mr T, a 20-year-old male, was taken to a psychiatrist by his parents with the request that he be "treated" for his homosexual orientation. They viewed his sexual orientation as abnormal and deviant, and felt that it was a "disease" which should be "cured". They sought a complete medical evaluation of their son, followed by conversion therapy.

"I want my son to become a successful engineer rather than suffer on the streets like hijras," were the words of his father. He claimed that psychiatrists "treat" these "erring males" and reconvert them into normal males through hormone therapy and electroconvulsive therapy. He insisted that his son be provided with these correctional therapies.

Mr T was in the third year of his graduate engineering course. He had a very lively campus life – he was good at academics and was an active member of the dramatics club. He enjoyed directing plays and had represented his college in inter-college meets. He had become aware of his sexual orientation during his stay in hostel, when he had felt attracted to his room-mate. He would find guys attractive and was surprised to find that he